Conference Reports for NATAP

Back

15th International HIV Drug Resistance Workshop June 13-17, 2006, Sitges, Spain     Development of virco®TYPE Resistance Analysis, including Clinical Cut-offs, for TMC114 (07/19/06)   Hepatitis C virus resistance to new antivirals (07/11/06)   Resistance to Enfuvirtide, Vicriviroc, and TMC125 (07/10/06)   Impact of optimised background regimen on virological response to TMC114 with low-dose ritonavir in POWER 1, 2 and 3, as measured by the phenotypic susceptibility score (07/05/06)   Everything you wanted to know (almost) about resistance to darunavir; discussion of cross-resistance and comparisons with tipranavir Written for NATAP by: Mark Mascolini - (07/05/06)   Primary infection with drug-resistant HIV Resistance Workshop Review: Part 4 Written for NATAP by: Mark Mascolini - (06/29/06)   Phenotypic Susceptibility to TMC-114 and Tipranavir Before and After Lopinavir/ritonavir-based Treatment in Subjects Demonstrating Evolution of Lopinavir Resistance - (06/27/06)   Clinically Relevant Virco Phenotypic Resistance and Cross Resistance to Tipranavir Among Recent Routine Clinical Isolates - (06/27/06)   Patterns of Tipranavir Susceptibility and Cross-Resistance Among Patient Samples Submitted for Routine Resistance Testing - (06/27/06)   ANALYSES OF SUSCEPTIBILITY AND CROSS-RESISTANCE BETWEEN TMC114 AND OTHER PROTEASE INHIBITORS AMONG >56,000 ROUTINE SAMPLES, USING LINEAR REGRESSION MODEL-BASED FOLD CHANGE PREDICTIONS - (06/27/06)   Preventing HIV transmission: prophylactic TDF/FTC and resistance to a vaginal microbicide Written for NATAP by: Mark Mascolini - (06/23/06)   Prevalence of Three-class Resistance in North Carolina cohort study; K65R & tenofovir response, and predicting salvage response to fosamprenavir/r Written for NATAP by: Mark Mascolini - (06/23/06)   Initial Virologic Failure with HIV Drug Resistance and Impact of Resistance on Disease Progression and Death for Patients Beginning PI, NNRTI or PI+NNRTI Based Strategies: The FIRST Study - (06/22/06)   Low-level Viremia Persists for at Least 7 years in Patients on Suppressive Antiretroviral Therapy, using real-time RT-PCR assay with single-copy sensitivity - (06/22/06)   Resistance Workshop Review: Part 1 PI monotherapy, Boosted vs unboosted atazanavir, STIs, first-line options (NNRTIs vs boosted PI vs unboosted PI) Written for NATAP by: Mark Mascolini - (06/21/06)   Evaluation of Resistance Patterns in Treatment-naive Subjects with Virologic Failure on Atazanavir- or Atazanavir/Ritonavir-containing Regimens - (06/21/06)   Brecanavir: new PI, resistance report from phase II study - (06/21/06)   New HCV Polymerase Inhibitor is in Early Development; resistance at 282 is associated with polymerase drug resistance, but PSI-6130 may remain active when mutation is present - (06/20/06)   New achievements in hepatitis C virus research and their implications for antiviral therapy - (06/20/06)   Impact of baseline K103N or Y181C on the virological response to the NNRTI TMC125: analysis of study TMC125-C223 - (06/20/06)   De-selection of the I50V mutation occurs in clinical isolates during Aptivus/r (tipranavir/ritonavir)-based therapy - (06/20/06)   Drug Resistance Outcomes in a Trial Comparing Lopinavir/ritonavir (LPV/r) Monotherapy to LPV/r + Zidovudine/Lamivudine (MONARK Trial) in treatment naives - (06/20/06)   More Drug Resistance Observed on NNRTIs than Boosted PI Regimens in Swiss HIV Cohort Study, Study Reports - (06/20/06)   Sensitive Genotyoic Test Detects Low-Level K65R Which Impairs Viral Response - (06/20/06)   Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3 - (06/19/06)   Drug Resistance Outcomes in a Trial Comparing Lopinavir/ritonavir (LPV/r) Monotherapy to LPV/r + Zidovudine/Lamivudine (MONARK Trial) in treatment naives - (06/19/06)   Selection of Protease Inhibitor Resistance Mutations During Virologic Failure of Lopinavir/ritonavir Monotherapy in an Induction-Maintenance Study - (06/19/06)   Selection of NNRTI resistant HIV-1 after discontinuation of a virologically suppressive regimen: standard genotype test does not detect all resistance - (06/19/06)   Antiviral Activity of SPI- 256 Against Wild- Type and Multidrug Resistant Strains - (06/19/06)   In Vitro Selection Strategy and Characterization of Resistance to a Novel Highly potent HIV Protease Inhibitor SPI-256 - (06/19/06)   Jules Levin's TOP 10 STORIES FROM Resistance Workshop - (06/16/06)   Protease Mutations Outside of Protease Gene Found in GAG Gene - (06/16/06)   AMBRILIA REPORTS POSITIVE PHASE IA RESULTS FOR ITS LEAD HIV/AIDS PROTEASE INHIBITOR PPL-100 - (06/16/06)   The HIV-1 Protease Inhibitor PL-100 Has a High Genetic Barrier and Selects a Novel Pattern of Mutations - (06/16/06)   SPI-256: a novel highly potent HIV protease inhibitor - (06/15/06)   Antiviral activity of SPI-256 against WT and MDR Strains - (06/15/06)   Tenofovir/FTC Prevents HIV Transmission in Monkeys - (06/15/06)   New HIV Protease Inhibitor PL-100 - (06/15/06)   Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor A-848837 in vitro - (06/14/06)   Merck's New HCV Polymerase Inhibitor Drug Reduces HCV Viral Load by 5.7 Log in 7 Days in Chimps - (06/14/06)